Navigation Links
Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
Date:2/13/2008

Competitive Advantages in Efficacy Will Drive Prescription Rates, According

to a New Report from Decision Resources

WALTHAM, Mass., Feb. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, following its approval in early 2009, Centocor/Janssen-Cilag's ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its competitive advantages in long-term efficacy over Centocor/Schering- Plough/Mitsubishi Tanabe's Remicade and due to its superior effect on plaque clearance when compared to Amgen/Wyeth/Takeda's Enbrel.

According to the new report entitled Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011, ustekinumab has competitive advantages in efficacy, the area of the highest importance to surveyed physicians, and a superior safety and delivery profile when compared to Remicade. Surveyed dermatologists report that a drug's effect on plaque clearance is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading Enbrel on this attribute.

"Clinical data and thought leader opinion indicate that ustekinumab and Abbott/Eisai's Humira outperform Enbrel on efficacy and delivery measures," said Irene Koulinska, analyst at Decision Resources. "But the major improvement in efficacy offered by ustekinumab will earn it future gold- standard status."

About the Report

Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011 is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
2. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
3. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
4. Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
5. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Solazyme Selected for National Institute of Standards and Technology Award
8. MyClyns(TM), a New Standard of Personal Protection, is Announced at the EMS and Firehouse Central EXPO
9. CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public
10. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... NBIX ) today announced its financial results for the quarter ... --> For the fourth quarter of 2015, the ... per share, compared to a net loss of $19.4 million, or ... the year ended December 31, 2015, the Company reported a net ... to a net loss of $60.5 million, or $0.81 loss per ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):